Ex Vivo-Activated Autologous Lymph Node Lymphocytes
Infectious Disease
Explore 2 assets in Infectious Disease →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Cell therapy
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02530515CT.gov Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Infectious Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ex Vivo-Activated Autologous Lymph Node Lymphocytes (this asset) | M.D. Anderson Cancer Center | P2 | B · 57 |
| Sulfamethoxazole | Radboud University Medical Center | P4 | A |
| Trimethoprim | Radboud University Medical Center | P4 | A |
| Ciprofloxacin | Radboud University Medical Center | P4 | BBB |
| Amdinocillin | Radboud University Medical Center | P4 | BB |
| Aztreonam | Liverpool Heart and Chest Hospital NHS Foundation Trust | P4 | BB |
| Nivestim | Cellerant Therapeutics | P3 | BB |
| Fosfomycin | Radboud University Medical Center | P4 | BB |
| Melphalan | City of Hope Medical Center | P2 | BB |
+40 more in the Infectious Disease cohort
Other indications for Ex Vivo-Activated Autologous Lymph Node Lymphocytes
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Anemia | — | P2 | B · 57 |
| Lymphatic System Disorder | — | P2 | B · 57 |
| Prolymphocytic Leukemia | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ex Vivo-Activated Autologous Lymph Node Lymphocytes in Infectious Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ex-vivo-activated-autologous-lymph-node-lymphocytes-infectious-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →